Please use this identifier to cite or link to this item:
|Title:||Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry||Authors:||Wang, L.-Z.
|Issue Date:||5-Mar-2012||Citation:||Wang, L.-Z., Ong, R.Y.-L., Chin, T.-M., Thuya, W.-L., Wan, S.-C., Wong, A.L.A., Chan, S.-Y., Ho, P.C., Goh, B.-C. (2012-03-05). Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 61 : 86-92. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jpba.2011.11.034||Abstract:||A novel and specific liquid chromatography-tandem mass spectrometric method (LC-MS/MS) was developed and validated for the quantification of hydroxychloroquine in human blood using its stable labeled isotope, hydroxychloroquine-d4 as the internal standard. Chromatographic separation of analytes was achieved using an Agilent ZORBAX Eclipse XDB - C8 analytical HPLC column (50mm×2.1mm, 5μm). The mobile phase comprising water containing 0.1% formic acid-acetonitrile (94:6, v/v) was delivered isocratically at a flow rate of 0.5mL/min. The column effluent was detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) and monitored by multiple reaction monitoring with positive mode. The precursor to product ion transitions of m/z 336→247 and m/z 340→251 were used to measure the analyte and IS, respectively. The assay demonstrated a good linear dynamic range of 5-2000ng/mL for hydroxychloroquine in human blood, with coefficient of determination (r 2) of =0.9999. The values for intra-day and inter-day precisions of hydroxychloroquine were ≤7.86% with the accuracies ranged from 93.8% to 107.6%. The chromatographic run time was 3min, making it possible to achieve a high throughput analysis. This method was used as a bio-analytical tool in a phase I clinical trial to quantify blood hydroxychloroquine concentrations in patients with non-small cell lung cancer receiving both hydroxychloroquine and gefitinib in their treatment. © 2011 Elsevier B.V.||Source Title:||Journal of Pharmaceutical and Biomedical Analysis||URI:||http://scholarbank.nus.edu.sg/handle/10635/110759||ISSN:||07317085||DOI:||10.1016/j.jpba.2011.11.034|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 22, 2021
WEB OF SCIENCETM
checked on Jan 14, 2021
checked on Jan 17, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.